# ArkVax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arkvax

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Latest round: Seed (Dec 5, 2022)
- Investors on record: 1

## About

Founded in 2020 by Brenden Wren and Jon Cuccui, and based in Cambridge, UK, ArkVax Limited was formed as a spinoff from the London School of Hygiene & Tropical Medicine (LSHTM) and operates as a biotechnology company that develops vaccines for protecting animals and cattle various bacterial diseases. In December 2022, new investor Start Codon raise an undisclosed amount of seed funding for ArkVax Limited.

ArkVax is a vaccine candidate development company that researches and develops vaccines and tests them directly in target animals to protect animals against various diseases. The firm uses technology to develop recombinant glycoconjugate vaccines in bacterial cells to help animals fight diseases and produce more milk/eggs.

The company intends to use the December 2022 funding to hire more teams and further develop its vaccine platform technology.

## Funding rounds

- Seed, Dec 5, 2022 — Start Codon

## Investors

- Start Codon (https://capitalatlas.ai/funds/start-codon) — Seed